beijing English news | beijing, Latest News & Live Updates in English | English News (Latest English News) at Lokmattimes.com

Beijing, Feb 17 A booster dose of China's first ever mRNA-based Covid vaccine may be potent against Omicron, according to a study.However, two doses of the vaccine called ARCoV has seen a significant drop in its ability to neutralise the Omicron strand of the coronavirus compared to its effectiveness against a wild-type strain with no major mutations, the South China Morning Post reported.ARCoV is being jointly developed by the Academy of Military Medical Sciences, Suzhou Abogen Biosciences, and Walvax Biotechnology, and is at the final stage of a multiregional phase 3 clinical trial.The vaccine is being developed using the same revolutionary mRNA technology, as the Pfizer-BioNTech and Moderna products.The study analysed serum samples from 11 vaccinated people, eight of whom "retained low but detectable neutralisation activity against Omicron", researchers said in a letter published in the journal Cell Research.A third dose was given to a group of lab mice that had already received two doses of ARCoV, and it readily induced the production of neutralising antibodies against Omicron and a wild-type strain, the letter said.The study highlighted the benefits of a homologous booster vaccination and supported further validation of the vaccine in clinical trials."Our data presented here clearly demonstrate that a third dose of ARCoV would probably lead to a sharp increase in neutralisation antibodies not only against the wild type SARS-CoV-2 but also the new Omicron variant," the letter said."Homologous booster vaccination with ARCoV represents a rational strategy in response to the Omicron emergency," it added.China has, so far, relied on traditional "inactivated" vaccines, which have been proved less effective against the Omicron and Delta variants.The ArCoV vaccine is the first mRNA vaccine candidate against the Omicron variant that has been validated in animals, the report said.Chinese researchers are approaching clinical trials to test its safety and efficacy, according to the study.Chinese regulators have also not approved any vaccine developed overseas.In July, last year, Shanghai-based Fosun Pharmaceuticals came closest by earning a recommendation from the government's expert panel for the Pfizer/BioNTech vaccine, the report said.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

BeijingFOLLOW

Beijing, Latest News

Tokyo, Feb 19 The International Atomic Energy Agency (IAEA) said that it will publish a report in April ... ...

Kathmandu, Feb 18 A small Himalayan nation, Nepal, has been caught in diplomatic wrangling between two superpowers, the ... ...

China's birth rate has dropped to a record low, with experts questioning Beijing's "one-child" policy, enforced with an iron hand, which is being blamed for the population conundrum visible in a rapidly ageing population and a shrinking workforce. ...

Exiled Chinese businessman Guo Wengui filed for bankruptcy protection after a New York judge ordered him to pay USD 134 million in fines for moving a yacht out of the reach of an unpaid lender. ...

Pakistan's Senate Standing Committee seek the equal representation of all the provinces in the China-Pakistan Economic Corridor (CPEC) authority and expressed concerns that there was a sense of "deprivation" among the provinces about the CPEC project ...

A new report by a Washington based think tank has accused the World Bank of "funding a campaign of repression" of Uygurs and other Muslim minorities in China's Xinjiang province. ...

The recent remarks of former Prime Minister Manmohan Singh on India's foreign policy are purely and clearly a political message, not a policy one, said the Ministry of External Affairs after Singh stated China is sitting at our border and efforts are ...

Beijing, Feb 17 A booster dose of China's first ever mRNA-based Covid vaccine may be potent against Omicron, ... ...